Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134341 · ClinicalTrials.gov registry record · Phase 1
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01134341 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 34 participants.
The verdict
NCT01134341, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.
Interventions
- DIETARY_SUPPLEMENT Vitamin B12
- DRUG Pralatrexate Injection
- DIETARY_SUPPLEMENT Folic Acid
- DRUG Bexarotene Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134341
The ClinicalTrials.gov registry entry for NCT01134341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vitamin B12 is the first listed.
NCT01134341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134341 about?
NCT01134341 is a clinical study titled "Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma". This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.
What is the current status of trial NCT01134341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01134341?
The interventions under investigation include: Vitamin B12 (DIETARY_SUPPLEMENT), Pralatrexate Injection (DRUG), Folic Acid (DIETARY_SUPPLEMENT), Bexarotene Capsules (DRUG).
Who is sponsoring clinical trial NCT01134341?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.